Abstract Animal and in vitro studies suggest that ursodeoxycholic acid (UDCA) can induce cytochrome P450 3A (CYP3A) expression and enhance its activities. On the other hand, Becquemont et al. demonstrated that UDCA had no influence on intestinal CYP3A activities. The aim of this study was to investigate the effects of UDCA on the intestinal and hepatic CYP3A activities by administration of midazolam (MDZ), as a specific probe for CYP3A activity, in humans. This was a randomized, open-label, crossover study with two phases in 14 healthy volunteers. The volunteers received UDCA (300 mg/day) or placebo orally for 9 days. The pharmacokinetics and pharmacodynamics of intravenous MDZ (5 μg/kg) and oral MDZ (15 μg/kg) were assessed on days 8 and 9, respectively. The pharmacodynamics of MDZ was estimated by measuring peak saccadic velocity, postural away length, critical fusion flicker frequency, and visual analogue scale. UDCA did not affect the pharmacokinetic and pharmacodynamic parameters of intravenous and oral MDZ administrations. Our study suggests that the clinical dosage of UDCA could not affect both hepatic and intestinal CYP3A activities and that the drug interaction between UDCA and substrates for CYP3A is unlikely in humans.
Introduction
Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, which was discovered in China 75 years ago, is a major ingredient of dried natural bile of the Chinese black bear and has been used as medicine to prevent biliary cholesterol stone formation in the treatment of several cholestatic liver diseases for a long time (Paumgartner and Beuers 2002; Becquemont et al. 2006; Macias et al. 2006) . Recently, a link has been shown to exist among UDCA, cytochrome P450 (CYP) levels and activities, and drug-transporting proteins, which implies that UDCA might cause the drug interaction (Zolner et al. 2003; Schuetz et al. 2001) .
CYP, a superfamily of enzymes, catalyzes the biotransformation of xenobiotics, including approximately 45-60% of the currently marketed drugs, lots of endogenous and environmental chemicals or toxicant, and has large impact on drug treatment (Burk and Wojnowski 2004; Thummel et al. 1996; Shimada et al. 1994; Bertz and Granneman, 1997; Rebbeck et al. 1998; Guengerich 1999) . CYP3As are present in the largest quantity of all the CYP, the expression status of which in different tissues plays a crucial role to determine largely the efficacy and safety of drug treatment (Dey et al. 2006) . In humans, four CYP3As are known to be expressed: CYP3A4, CYP3A5, CYP3A7, and CYP3A43. CYP3A4 is the most abundant CYP, contributing to the metabolism of the largest percentage of clinically used drugs and accounting for the large number of clinically documented drug interactions (Domanski et al. 2001; Westlind et al. 2001; Floyd et al. 2003) . Moreover, a large amount of CYP3A is found not only in liver but also in small intestine, and levels of the CYP3A appear to be independently regulated at the two anatomical sites (Lown et al. 1994; Thummel et al. 1996) . Hence, CYP3A-mediated metabolism in liver or small intestine could be changed when orally taking drugs that affect CYP3A.
Previous data in animal model or ex vivo studies have suggested that UDCA could increase the CYP3A activity (Paumgartner and Beuers, 2002; Schuetz et al. 2001; Paolini et al. 2002; Becquemont et al. 2006) . On the other hand, it has been shown in humans that UDCA did not affect CYP3A4 mRNA expression in intestine and the pharmacokinetics of oral midazolam (MDZ), a probe for CYP3A4 activity. Then, to confirm whether UDCA affects not only intestinal CYP3A4 but also hepatic CYP3A4 in humans, we tested the effect of UDCA on both hepatic and intestinal CYP3A activities by estimating both the pharmacokinetics and pharmacodynamics of MDZ following the oral and intravenous administration in healthy volunteers.
Materials and methods

Subjects
Fourteen healthy volunteers (eight men and six women; age, 23.0±2.3 years; weight, 59.5±9.4 kg) participated in the study. Each subject was ascertained to be in good health, by medical history, clinical examination, and standard hematologic and regular blood biochemical tests, and having no addiction or bad habits. The volunteers were not using any continuous medication and all of them were nonsmokers. The subjects provided their written informed consent before participation in the study. The study protocol was approved by the Ethics Committee of Hamamatsu University School of Medicine and abided by the Declaration of Helsinki.
Study design
A randomized, open-label, crossover study design with two phases was used at an interval of 2 weeks. The volunteers took either UDCA (URSO® tablet, 100 mg, Mitsubishi Pharm, Japan) or placebo t.i.d. (at 0600-0800, 1100-1300, and 1900-2100 hours) for 9 days. The dose of UDCA was 300 mg/day. Probe drugs, intravenous 5 μg/kg MDZ (Dormicum \ , 5 mg/ml injection; Astellas Pharma,Tokyo, Japan) and oral 15 μg/kg MDZ were administered after an overnight fast on days 8 and 9, respectively. Consumption of grapefruit or orange products during the study period (from 7 days before the experimental onset) was forbidden. Approximately 4 h after the administration of MDZ, the volunteers ingested a warm standard meal.
Samplings
A forearm vein of each subject was cannulated with a plastic cannula. Timed blood samples were drawn into ethylenediaminetetraacetic acid disodium salt (EDTA2Na)-containing tubes immediately before and at 5, 15, and 30 min and 1, 1.5, 2, 4, 6, 8, 10 , and 24 h after intravenous MDZ administration on day 8, and before and at 30 min and 1, 1.5, 2, 3, 4, 6, 8, 10 , and 24 h after oral MDZ administration on day 9. The plasma was isolated from blood sample and then stored at −80°C until analysis. In addition, the 24-h urine was collected after both intravenous and oral MDZ administration. The urine sample was stored at −80°C until analysis.
Measurements of MDZ and its metabolites
Sample (5 μl) was analyzed in a TSQ7000C (Thermo Electron, Waltham, MA, USA) equipped with a spectra SYSTEM (Thermo Electron). Chromatographic separation was achieved under isocratic conditions on a C 18 column with a guard column (Symmery; 2.1×10 mm, 0.35 μl; Waters, Milford, MA, USA). The column temperature was the same as room temperature. The mobile phase for the assay consisted of methanol and 10 mM ammonium acetate 
Pharmacokinetic analysis
Pharmacokinetic parameters for MDZ and 1′-OH MDZ were estimated by noncompartmental analysis from the concentration-time profile in plasma by use of WinNonlin software (version 4.1, Pharsight, Mountain View, CA, USA). The half-life (t 1/2 ) during the log-linear terminal phase was calculated from the elimination rate constant (λ) determined by linear regression analysis of the log-linear part of the plasma concentration-time curve. The area under the plasma concentration-time curves from 0 to 24 h postdose (AUC 0-24 ) was calculated by the trapezoidal rule. The area under the curve (AUC) from time 0 to infinity (AUC 0À1 ) was calculated as AUC 0À1 ¼ AUC 0À24 þ C t =λ, where C t is the last plasma concentration measured. The oral clearance (CL/F) was calculated as dose=AUC 0À1 , and the apparent volume of distribution (Vd/F) was obtained by dividing CL/F by λ. The maximum plasma concentration (C max ) was read directly from the observed plasma concentration-time data.
The ratio for AUC 0-24 of MDZ to AUC 0-24 of 1′-OH MDZ (AUC MDZ /AUC 1′-OH MDZ ) was calculated.
Measurements of pharmacological effects of MDZ
The pharmacological effects of MDZ on all participants were estimated at 0 and 15 min in intravenous MDZ and 0 and 1 h in the oral MDZ, respectively. Peak saccadic velocity (PSV) of eye movement, postural sway length (PSL), critical fusion flicker (CFF) frequency, and visual analogue scale (VAS) were chosen as the pharmacological indices of MDZ. PSV was measured as described previously (Amlot et al., 2003; Van et al., 1991) . The horizontal eye movements were recorded by a stimulus device (SLE-5100, Nihon Kohden, Tokyo, Japan), and the signal collection and analysis were carried out by a Neuropack MEB-558 (Nihon Kohden, Tokyo, Japan). In brief, eye and target movements were sampled on-line at 200 Hz using a 12-bit analog-to-digital converter. Head movements were restricted using a bite bar. Each recording session began and ended with a calibration test. This comprised light-emitting diode (LED) jumps with amplitudes of 5, 10, 15, 20, and 25°to and from the central position in both directions. Two paradigms of reflexive visually guided saccades were successively tested. In each paradigm, one lateral LED was randomly presented 25°to either the right or left of the central LED on the horizontal meridian in each of the sixty trials. In the gap paradigm, subjects fixated a central fixation target illuminated for 2-4 s. Approximately 200 ms after the central target was extinguished, a lateral target was switched on for 500 ms. Subjects were asked to move their eyes to the lateral target as quickly as possible when it appeared. Trials were separated by a 10-s interval, during which no stimuli were presented. In the overlap paradigm, the central fixation target remained switched on All data are given as mean±SD. C max Peak plasma concentration; t 1/2 elimination half-life; AUC 0-24 area under concentration-time curve from 0 to 24 h during presentation of the lateral target. All other conditions were the same as for the gap task. PSL test was assessed by Gravicorder (G-5500, Anima, Tokyo, Japan) as described by Thomas et al. (2001) . Subjects closed their eyes, stood for 30 s, and then the postural sway length was observed. CFF was monitored as described by Olkkola KT et al. (Theofilopoulos et al. 1984; Kosuge et al. 2001) . In a word, CFF was assessed by a flickering light giving rise to the subjective sensation of a steady light. A Flicker Fusion Monitor (DF-1, Sibata Scientific Technology, Tokyo, Japan) was used. Subjects stood and closed their eyes and were shaken for 30 s and then viewed the stimulus through a 2-mm 'artificial pupil'. Three measurements of the threshold were recorded at decreasing frequencies, and the mean of the three measurements was taken.
VAS was performed to record subjective effects, and the questions on the sides of visual analogue scales were the same as previously described (Bond and Lader 1974; Olkkola et al. 1993 ).
Statistical analysis
All values are represented as mean ± SD. When the significant difference was discussed, statistical analysis was carried out by Statcel software (ver 2.0, OMS, Saitama, Japan) through paired t test for the pharmacokinetic parameters and the pharmacodynamic indices. P values <0.05 were considered to be statistically significant.
Results
Effect of UDCA on pharmacokinetics of MDZ and 1′-OH MDZ after intravenous MDZ administration
Plasma concentration-time profiles of MDZ and 1′-OH MDZ after intravenous MDZ administration are shown in Fig. 1a and b , respectively, and the corresponding pharmacokinetic parameters are summarized in Tables 1 and 2 . The plasma concentration of MDZ and 1′-OH MDZ could be detected up to 10 h after injection and then lowered under the limit of detection at 24 h. There were no statistically significant differences in the pharmacokinetic parameters of MDZ and 1′-OH MDZ between the UDCA and placebo. Another metabolite, 4-OH MDZ, could not be detected at any time points.
Effect of UDCA on pharmacokinetics of MDZ and 1′-OH MDZ after oral MDZ administration
To estimate changes in the intestinal CYP3A activity by UDCA, we tested the effects of UDCA on pharmacokinetics of oral MDZ and its metabolites at the same time. As shown in Fig. 2a and b , the plasma concentration-time relationships of MDZ and 1′-OH MDZ were not significantly changed by oral administration of UDCA when compared to placebo. The plasma levels of MDZ and 1′-OH MDZ were under the limit of detection at 24 h, and 4-OH MDZ could not be detected at any time points. UDCA did not affect the pharmacokinetic parameters of MDZ and 1′-OH MDZ after oral MDZ administration (Tables 3 and 4) .
Effect of UDCA on pharmacological responses of intravenous MDZ administration
In addition to the pharmacokinetic parameters, we estimated the effect of UDCA on pharmacodynamics of MDZ before and 15 min after intravenous MDZ administration. The intravenous dose of MDZ affected only VAS significantly, while it did not affect the other indices, PSL, PSV, and CFF, as shown in Fig. 3 . UDCA did not influence the changes of VAS by intravenous MDZ (12.8±18.6 mm in placebo vs 18.3±20.2 mm in UDCA, P>0.05).
Effect of UDCA on pharmacological responses of oral MDZ administration
We also tested the effect of UDCA on pharmacological responses of MDZ before and 1 h after oral MDZ administration. As shown by the results of intravenous MDZ administration, the oral dose of MDZ affected only (Fig. 4) . UDCA did not affect the changes of VAS by oral MDZ (40.4 ±30.6 mm in placebo vs 29.6 ±26.6 mm in UDCA, P >0.05).
Discussion
In this study, we confirmed that UDCA has no effect on both intestinal and hepatic CYP3A activities in healthy volunteers. Becquemont et al. already showed that UDCA did not affect intestinal CYP3A indicating no effects of UDCA on CYP3A4 mRNA expression in intestine and oral MDZ pharmacokinetics in human. We confirmed that our data related to the effect of UDCA on intestinal CYP3A, the pharmacokinetics of oral MDZ administration, are consistent with Becquemont's result and showed for the first time that UDCA has no effect on hepatic CYP3A, the pharmacokinetics of intravenous MDZ administration as well as intestinal CYP3A, and on pharmacodynamics of oral and intravenous MDZ administrations. Because MDZ possesses lots of the characteristics of an ideal and validated CYP3A probe, MDZ has been widely used to study the drug interaction through CYP3A (Watkins 1994; Dostalek et al. 2005) , especially CYP3A4/3A5 (Krecic-Shepard et al. 1999) . MDZ is metabolized exclusively by CYP3A, mainly yielding 1′-OH MDZ and less 4-OH MDZ (Wandel et al. 1994) . MDZ is also widely used as a hypnotic and sedative drug for hypnosis, preoperative sedation, induction and maintenance of anesthesia, and sedation of patients in intensive care units. These situations indicate that MDZ is likely to be exposed with other drugs. Some reports described that the concomitant use of CYP3A inhibitors or inducers such as ketoconazole, itraconazole, atorvastatin, fluvastatin, and saqunavir markedly changed the plasma concentration and pharmacological effects of MDZ, which suggested that pharmacokinetics and pharmacodynamics of MDZ could be affected by agents that influence the activity and expression of CYP3A (Strelevitz et al. 2006; Emoto et al. 2005 Emoto et al. , 2003 Tsunoda et al. 1999; McDonnell et al. 2003) .
Recently, some in vitro findings have shown that UDCA can induce the transcription of CYP3A4 (Zolner et al. 2003; Schuetz et al. 2001) and that natural bile acid can induce CYP3A (Bock and Lammert 2002; Schuetz et al. 1993) . Paolini et al. (2002) showed that UDCA induces hepatic CYP3A in mice. Bodin et al. (2001) indicated that high dose of UDCA (1,000 mg/day) can augment CYP3A4 activities by estimating plasma levels of 4ß-hydroxycholesterol, which is metabolized by CYP3A4, in humans. In addition to these findings, recently, it has been shown that UDCA itself is a substrate of CYP3A4 (Bodin et al. 2005 ) and considered as one of the regulators for liver function. All the above evidences show that there could be interaction between UDCA and CYP3A substrates. On the other hand, Becquemont et al. showed that UDCA induced multidrug resistance 1 (MDR1)/P-glycoprotein (P-gp) and CYP3A4 mRNA levels in Caco-2 cells but not in LS174T cells in vitro. However, UDCA had no detectable effects on the pharmacokinetics of oral MDZ or the intestinal mRNA and protein expression levels of MDR1/P-gp and CYP3A4, although UDCA modestly decreased disposition of digoxin, an MDR1/P-gp probe, in a clinically relevant manner (Becquemont et al. 2006 ). The present study confirmed that UDCA had no detectable effects on oral MDZ pharmacodynamics as well as its pharmacokinetics in healthy volunteers, which is consistent with the results shown by Becquemont et al.
We evaluated both hepatic and intestinal CYP3A activities by testing the different routes of administration of MDZ: intravenous and oral MDZ. A relatively large amount of CYP3A is found in the enterocytes of the small intestine and in hepatocytes, and this combined localization is responsible for the often marked oral first-pass metabolism of many of its substrates (Thummel et al. 1997; Paine et al. 1996) . Grapefruit is a well-documented inhibitor of intestinal CYP3A4 but not hepatic CYP3A4 and interacts with many drugs. Coadministration with grapefruit juice did not alter the pharmacokinetics and pharmacodynamics of intravenous MDZ, whereas after an oral dose of MDZ, grapefruit juice significantly increased the peak plasma concentration by 56% and the AUC by 52% (Kupferschmidt et al. 1995) . Hence, it should be critical to test both hepatic and intestinal CYP3A when the effects of oral drugs on CYP3A are evaluated. Administration of MDZ by both the intravenous and oral routes makes it possible to obtain separate quantitative estimates of hepatic and intestinal CYP3A metabolism . The results of this study demonstrated that UDCA had no influence on the pharmacokinetics and pharmacodynamics of MDZ even if MDZ was administered intravenously or orally.
In conclusion, in this study, UDCA had no detectable effects on pharmacokinetics and pharmacodynamics of both oral and intravenous MDZ. Thus, our data demonstrate that the clinical dosage of UDCA could not affect both hepatic and intestinal CYP3A activities in humans.
